Prolonged erection defi ned as erection lasting > 4 to < D6 hours in duration occurred in 4% of 1,861 patients treated up to 18 months in studies of CAVERJECT Sterile Powder. The incidence of priapism (erections lasting > 6 hours in duration) was 0.4% with the same length of use. Pharmacologic intervention and/or aspiration of blood from the corpora cavernosum was performed in 2 of the 7 patients with priapism. To minimize the chances of prolonged erection or priapism, CAVERJECT should be titrated slowly to the lowest effective dose (see DOSAGE AND ADMINISTRATION). The patient must be instructed to immediately report to his prescribing physician, or, if unavailable, to seek immediate medical assistance for any erection that persists longer than 4 hours. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.
- CAVERJECT IMPULSE (alprostadil dual chamber system for injection) is designed for one use only. Following a single use, the injection device and any remaining solution should be properly discarded.
- The overall incidence of penile fi brosis, including Peyronie's disease,
reported in clinical studies with CAVERJECT Sterile Powder was 3%. In one
self-injection clinical study where duration of use was up to 18 months, the
incidence of fibrosis was 7.8%.
Regular follow-up of patients, with careful examination of the penis, is strongly recommended to detect signs of penile fibrosis. Treatment with CAVERJECT should be discontinued in patients who develop penile angulation, cavernosal fibrosis, or Peyronie's disease.
- Intracavernous injections of CAVERJECT can lead to increased peripheral blood levels of PGE1 and its metabolites, especially in those patients with signifi cant corpora cavernosa venous leakage. Increased peripheral blood levels of PGE1 and its metabolites may lead to hypotension and/or dizziness.
- Patients on anticoagulants, such as warfarin or heparin, may have increased propensity for bleeding after intracavernosal injection.
- Underlying treatable medical causes of erectile dysfunction should be diagnosed and treated prior to initiation of therapy with CAVERJECT.
- The safety and effi cacy of combinations of CAVERJECT and other vasoactive agents have not been systematically studied. Therefore, the use of such combinations is not recommended.
- CAVERJECT IMPULSE (alprostadil dual chamber system for injection) uses a superfi ne (29 gauge) needle. As with all superfine needles, the possibility of needle breakage exists. Careful instruction in proper patient handling and injection techniques may minimize the potential for needle breakage.
- The patient should be instructed not to re-use or to share needles or syringes. As with all prescription medicines, the patient should not allow anyone else to use his medicine.
Information for the Patient
To ensure safe and effective use of CAVERJECT, the patient should be thoroughly instructed and trained in the self- injection technique before he begins intracavernosal treatment with CAVERJECT at home. The desirable dose should be established in the physician's office.
Any reconstituted solution with precipitates or discoloration should be discarded. The CAVERJECT IMPULSE (alprostadil dual chamber system for injection) syringe system is designed for one use only and should be discarded after use. The device and the needle must be properly discarded after use. Needles must not be re-used or shared with other persons. Patient instructions for administration are included in each package of CAVERJECT IMPULSE.
The dose of CAVERJECT that is established in the physician's offi ce should not be changed by the patient without consulting the physician. The patient may expect an erection to occur within 5 to 20 minutes. A standard treatment goal is to produce an erection lasting no longer than 1 hour. Generally, CAVERJECT should be used no more than 3 times per week, with at least 24 hours between each use.
Patients should be aware of possible side effects of therapy with CAVERJECT; the most frequently occurring is penile pain after injection, usually mild to moderate in severity. A potentially serious adverse reaction with intracavernosal therapy is priapism. Accordingly, the patient should be instructed to contact the physician's offi ce immediately or, if unavailable, to seek immediate medical assistance if an erection persists for longer than 4 hours.
The patient should report any penile pain that was not present before or that increased in intensity, as well as the occurrence of nodules or hard tissue in the penis to his physician as soon as possible. As with any injection, an infection is a possibility. Patients should be instructed to report to the physician any penile redness, swelling, tenderness or curvature of the erect penis. The patient must visit the physician's offi ce for regular checkups for assessment of the therapeutic benefit and safety of treatment with CAVERJECT.
Note: Use of intracavernosal CAVERJECT offers no protection from the transmission of sexually transmitted diseases. Individuals who use CAVERJECT should be counseled about the protective measures that are necessary to guard against the spread of sexually transmitted diseases, including the human immunodefi ciency virus (HIV).
The injection of CAVERJECT can induce a small amount of bleeding at the site of injection (see ADVERSE REACTIONS section hematoma, ecchymosis, hemorrhage at the site of injection). In patients infected with blood-borne diseases, this could increase the risk of transmission of blood-borne diseases between partners.
In clinical trials, concomitant use of agents such as antihypertensive drugs, diuretics, antidiabetic agents (including insulin), or non-steroidal anti-inflammatory drugs had no effect on the efficacy or safety of CAVERJECT.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term carcinogenicity studies have not been conducted. Rat reproductive studies indicate that alprostadil at doses of up to 0.2 mg/kg/day does not adversely affect or alter rat spermatogenesis, providing a 200-fold margin of safety compared with the usual human doses. The following battery of mutagenicity assays revealed no potential for mutagenesis: bacterial mutation (Ames), alkaline elution, rat micronucleus, sister chromatid exchange, CHO/HGPRT mammalian cell forward gene mutation, and unscheduled DNA synthesis (UDS).
A 1-year irritancy study was conducted in three groups of 5 male Cynomolgus monkeys injected intracavernosally twice weekly with either vehicle or 3 or 8.25 mcg of alprostadil/ injection. An additional two groups of 6 monkeys each were injected with vehicle or with 8.25 mcg/injection twice weekly as described previously plus they receive multiple doses during weeks 44, 48, and 52. Three monkeys from each group were retained for a 4-week recover period. There was no evidence of drug-related penile irritancy or nonpenile tissue lesions, which could be directl related to alprostadil. The irritancy, which was noted for control and treated monkeys, was considered to be a resul of the injection procedure itself and any lesions noted were shown to be reversible. At the end of the 4-week recover period, the histological changes in the penis had regressed.
Pregnancy, Nursing Mothers, and Pediatric Use
CAVERJECT is not indicated for use in pediatric patients or women.
A total of 341 subjects included in clinical studies were 65 and older. No overall differences in safety and effectivenes were observed between these subjects and younger subjects, and the other reported clinical experience has no identifi ed differences in responses between elderly and younger patients, but decreased sensitivity of some olde individuals cannot be ruled out.
Last reviewed on RxList: 3/4/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Caverject Impulse Information
Caverject Impulse - User Reviews
Caverject Impulse User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Sex & Relationships
Get tips to boost your love life.